A low-dose of a cheap drug widely used to treat gout could reduce the risk of heart attack and stroke in people already living with heart disease, finds a to a new analysis. The findings are based on a major Cochrane review, which suggests that colchicine, a long-established medication for treating inflammation and pain could have a powerful role beyond its traditional use.What Did The Study Find?Colchicine is one of the first-line treatments for gout on the NHS, commonly prescribed to ease the sudden and severe joint pain associated with the condition. But researchers have long suspected that its anti-inflammatory properties may benefit people with cardiovascular disease as well. The new Cochrane review strengthens that theory.The review analyzed 12 clinical trials involving 22,983 participants with a history of heart disease, previous heart attacks, or stroke. Out of these, 11,524 individuals were assigned a low daily dose of colchicine, typically 0.5 mg taken once or twice a day, and were monitored for cardiovascular outcomes over several months.According to the findings, people with existing cardiovascular disease who took colchicine for at least six months were less likely to experience major cardiovascular events such as heart attacks or strokes. Researchers noted that inflammation plays a key role in plaque buildup and instability in the arteries, and colchicine’s ability to dampen inflammation may help reduce these risks.Significant Reduction in Heart Attacks and StrokesThe review’s authors highlighted that the protective effect was clear and consistent across the trials. For every 1,000 people treated with low-dose colchicine, there were nine fewer heart attacks and eight fewer strokes compared with those who did not take the medication. While these numbers may appear modest, experts point out that at a population level, such reductions can translate into thousands of prevented events.“Reductions like this can make a real difference for patients who live with ongoing, lifelong cardiovascular risk,” said Dr Ramin Ebrahimi, co-lead author from University Medicine Greifswald in Germany. The findings suggest that colchicine could become an accessible addition to current heart-disease prevention strategies, especially given its low cost and widespread availability.Mild Side Effects NotedDespite its potential benefits, colchicine is not risk-free. Participants taking the drug reported a higher incidence of gastrointestinal side effects, such as stomach discomfort or mild digestive issues. These reactions, however, were generally not severe enough to require discontinuing the medication.Dr Lars Hemkens, senior author from the University of Bern in Switzerland, emphasized the importance of the findings, noting: “These results come from publicly funded trials repurposing a very old, low-cost drug for an entirely new use. It shows the power of academic research to reveal treatment opportunities that traditional drug development often overlooks,” as reported by Independent.How Colchicine WorksAccording to the NHS, colchicine works by reducing inflammation triggered by the buildup of uric acid crystals in the joints, a hallmark of gout. Its anti-inflammatory action helps ease pain flare-ups. The medication is typically supplied in 500-microgram tablets, although the exact dosage varies depending on the individual's condition and treatment plan.With growing evidence pointing toward its cardiovascular benefits, researchers say colchicine may soon be considered not just a gout medication, but a valuable tool in heart-disease prevention.
Email
Google
Facebook Email Google Facebook